The Institute is based in the science quarter at the heart of the university campus and is part of the School of Pharmacy and Medical Sciences, Faculty of Life Sciences.
Our research encompasses the development of new cancer medicines from concept to clinic. The emphasis of our work is on drug target and biomarker interrogation in clinical samples and development of relevant in vitro and in vivo models for lead compound selection and progression. Research covers the three broad stages of cancer medicine and biomarker development: discovery, pre-clinical evaluation and clinical application. We also provide GCLP PKPD laboratory support for the Leeds-Bradford Experimental Cancer Medicines Centre.
Our research activities and client services are all described in our new ICT Brochure 2017
- We are one of a few centres nationally that has all the necessary research tools and expertise in-house to progress anticancer medicines and biomarkers from concept to the clinic
- The REF2014 assessment (Allied Health) placed 92% of the Institute’s research outputs in the 4* and 3* categories, and 100% of its impact and environment studies in the 4* and 3* categories
- Our research programmes include Phase I clinical trial support through partnership with St James’s University Hospital as well as other regional hospitals